Integrated Omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact

Cancer results from processes prone to selective pressure and dysregulation acting along the sequence-to-phenotype continuum DNA → RNA → protein → disease. However, the extent to which cancer is a manifestation of the proteome is unknown. Here we present an integrated omic map representing non-small cell lung carcinoma. Dysregulated proteins not previously implicated as cancer drivers are encoded throughout the genome including, but not limited to, regions of recurrent DNA amplification/deletion. Clustering reveals signatures composed of metabolism proteins particularly highly recapitulated between patient-matched primary and xenograft tumours. Interrogation of The Cancer Genome Atlas reveals cohorts of patients with lung and other cancers that have DNA alterations in genes encoding the signatures, and this was accompanied by differences in survival. The recognition of genome and proteome alterations as related products of selective pressure driving the disease phenotype may be a general approach to uncover and group together cryptic, polygenic disease drivers.

[1]  Andreas Bracher,et al.  The molecular architecture of the eukaryotic chaperonin TRiC/CCT. , 2012, Structure.

[2]  P. Stover,et al.  SHMT1 and SHMT2 Are Functionally Redundant in Nuclear De novo Thymidylate Biosynthesis , 2009, PloS one.

[3]  Matthias Mann,et al.  High recovery FASP applied to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers. , 2011, Journal of proteome research.

[4]  Sharon J. Diskin,et al.  Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms , 2008, Nucleic acids research.

[5]  Gordon B. Mills,et al.  Derailed endocytosis: an emerging feature of cancer , 2008, Nature Reviews Cancer.

[6]  V. Denis,et al.  Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells , 2008, Molecular Cancer.

[7]  Aik Choon Tan,et al.  Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.

[8]  S. Gygi,et al.  Correlation between Protein and mRNA Abundance in Yeast , 1999, Molecular and Cellular Biology.

[9]  G. Parmigiani,et al.  Design and analysis issues in genome-wide somatic mutation studies of cancer. , 2009, Genomics.

[10]  M. Yaffe,et al.  The t-complex polypeptide 1 complex is a chaperonin for tubulin and actin in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Finley,et al.  Oxygen-dependent expression of cytochrome c oxidase subunit 4-2 gene expression is mediated by transcription factors RBPJ, CXXC5 and CHCHD2 , 2013, Nucleic acids research.

[12]  Christian M. Metallo,et al.  Metabolic pathway alterations that support cell proliferation. , 2011, Cold Spring Harbor symposia on quantitative biology.

[13]  Mark T. W. Ebbert,et al.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.

[14]  M. Moran,et al.  Primary tumor xenografts of human lung adeno and squamous cell carcinoma express distinct proteomic signatures. , 2011, Journal of proteome research.

[15]  Pan Du,et al.  lumi: a pipeline for processing Illumina microarray , 2008, Bioinform..

[16]  L. Meyer,et al.  Treatment of acute leukemia with amethopterin (4-amino, 10-methyl pteroyl glutamic acid). , 1950, Acta haematologica.

[17]  P. Stover,et al.  Serine Hydroxymethyltransferase Anchors de Novo Thymidylate Synthesis Pathway to Nuclear Lamina for DNA Synthesis* , 2012, The Journal of Biological Chemistry.

[18]  Joshua F. McMichael,et al.  Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.

[19]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[20]  M. Mann,et al.  Ultra High Resolution Linear Ion Trap Orbitrap Mass Spectrometer (Orbitrap Elite) Facilitates Top Down LC MS/MS and Versatile Peptide Fragmentation Modes* , 2011, Molecular & Cellular Proteomics.

[21]  G. Scagliotti,et al.  Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  Michael Levitt,et al.  Subunit order of eukaryotic TRiC/CCT chaperonin by cross-linking, mass spectrometry, and combinatorial homology modeling , 2012, Proceedings of the National Academy of Sciences.

[23]  G I Murray,et al.  Characterization and over‐expression of chaperonin t‐complex proteins in colorectal cancer , 2006, The Journal of pathology.

[24]  M. Mann,et al.  Andromeda: a peptide search engine integrated into the MaxQuant environment. , 2011, Journal of proteome research.

[25]  Roland Nilsson,et al.  A Computational Screen for Regulators of Oxidative Phosphorylation Implicates SLIRP in Mitochondrial RNA Homeostasis , 2009, PLoS genetics.

[26]  Somasekar Seshagiri,et al.  Comparative oncogenomics identifies PSMB4 and SHMT2 as potential cancer driver genes. , 2014, Cancer research.

[27]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[28]  D. Jayne,et al.  Retinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker. , 2013, European journal of cancer.

[29]  이연수.  Functional genomics reveal that the serine synthesis pathway is essential in breast cancer , 2011 .

[30]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[31]  W. Kaelin,et al.  Diverse Effects of Mutations in Exon II of the von Hippel-Lindau (VHL) Tumor Suppressor Gene on the Interaction of pVHL with the Cytosolic Chaperonin and pVHL-Dependent Ubiquitin Ligase Activity , 2002, Molecular and Cellular Biology.

[32]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[33]  S. Knuutila,et al.  CDK4 is a probable target gene in a novel amplicon at 12q13.3–q14.1 in lung cancer , 2005, Genes, chromosomes & cancer.

[34]  Juan R. González,et al.  R-Gada: a fast and flexible pipeline for copy number analysis in association studies , 2010, BMC Bioinformatics.

[35]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[36]  P. Robson,et al.  Glycine Decarboxylase Activity Drives Non-Small Cell Lung Cancer Tumor-Initiating Cells and Tumorigenesis , 2012, Cell.

[37]  R. Greenberg,et al.  A BRISC-SHMT complex deubiquitinates IFNAR1 and regulates interferon responses. , 2013, Cell reports.

[38]  M. Moran,et al.  Proteomic profiles of human lung adeno and squamous cell carcinoma using super‐SILAC and label‐free quantification approaches , 2014, Proteomics.

[39]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[40]  Robert J. Schumacher,et al.  Maturation of Human Cyclin E Requires the Function of Eukaryotic Chaperonin CCT , 1998, Molecular and Cellular Biology.

[41]  Allen Waziri,et al.  Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma. , 2013, Neuro-oncology.

[42]  Andreas Bracher,et al.  Molecular chaperones in protein folding and proteostasis , 2011, Nature.

[43]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[44]  L. Toledo-Sherman,et al.  New targets for an old drug , 2004, Clinical Proteomics.

[45]  Zhandong Liu,et al.  Serine catabolism regulates mitochondrial redox control during hypoxia. , 2014, Cancer discovery.

[46]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[47]  B. Fridley,et al.  Serine hydroxymethyltransferase 1 and 2: gene sequence variation and functional genomic characterization , 2012, Journal of neurochemistry.

[48]  Igor Jurisica,et al.  Prognostic gene signatures for non-small-cell lung cancer , 2009, Proceedings of the National Academy of Sciences.

[49]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[50]  Gregory Stephanopoulos,et al.  Amplification of phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis , 2012, BMC Proceedings.

[51]  N. Shah,et al.  Glycine Decarboxylase Activity Drives Non-Small Cell Lung Cancer Tumor-Initiating Cells and Tumorigenesis , 2012 .

[52]  M. Mann,et al.  Extensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma , 2012, Molecular systems biology.

[53]  T. Pan,et al.  Overexpression of initiator methionine tRNA leads to global reprogramming of tRNA expression and increased proliferation in human epithelial cells. , 2013, RNA.

[54]  V. Mootha,et al.  Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer , 2014, Nature Communications.

[55]  P. Massion,et al.  In-depth Proteomic Analysis of Nonsmall Cell Lung Cancer to Discover Molecular Targets and Candidate Biomarkers* , 2012, Molecular & Cellular Proteomics.

[56]  Johannes Griss,et al.  The Proteomics Identifications (PRIDE) database and associated tools: status in 2013 , 2012, Nucleic Acids Res..

[57]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[58]  F. Bossa,et al.  In silico and in vitro validation of serine hydroxymethyltransferase as a chemotherapeutic target of the antifolate drug pemetrexed. , 2011, European journal of medicinal chemistry.

[59]  E. Barillot,et al.  Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic Tumors , 2010, Clinical Cancer Research.

[60]  M. Tsao,et al.  The Ability to Form Primary Tumor Xenografts Is Predictive of Increased Risk of Disease Recurrence in Early-Stage Non–Small Cell Lung Cancer , 2010, Clinical Cancer Research.

[61]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[62]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[63]  R. Williams,et al.  Cytoplasmic chaperonin containing TCP-1: structural and functional characterization. , 1997, Biochemistry.

[64]  Isabelle Robert,et al.  Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer , 2007, Proceedings of the National Academy of Sciences.

[65]  K. Suk,et al.  Identification of novel cell migration‐promoting genes by a functional genetic screen , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[66]  R. Dinarvand,et al.  A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis , 2013, Cancer Chemotherapy and Pharmacology.

[67]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[68]  David E. Misek,et al.  Discordant Protein and mRNA Expression in Lung Adenocarcinomas * , 2002, Molecular & Cellular Proteomics.